Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

The purpose of this study is to examine the effectiveness and safety of the abatacept administration in biologic-naïve rheumatoid arthritis patients who have moderate disease activity despite treatments with conventional synthetic disease modified anti-rheumatic drugs.

Inclusion Criteria:

• Patients with RA who meet the 2010 American College of Rheumatology / European League against Rheumatisms (ACR/EULAR) RA Classification Criteria

• Patients with RA with a moderate disease activity (SDAI: > 11 and 26)

• Biologic-naive patients with treatment history csDMARDs

• Patients who meet the following criteria by hematological examination:

  • Peripheral white blood cell count: 4,000/mm3
  • Peripheral lymphocyte count: 1,000/mm3
  • Blood β-D-glucan negative

• Patients who understand the investigator's explanation of study procedures and have given voluntary written consent to participate in this study

• Patients initiated with abatacept at per their physician's therapeutic decision

Exclusion Criteria:

• Past history of hypersensitivity to the components of the abatacept preparation
• Disease complications from a comorbidity
• Active infectious disease
• Been judged by the investigator or the co-investigator as being inappropriate

Other protocol defined inclusion/exclusion criteria could apply